The Association Between PCSK9 Inhibitor Use and Sepsis: A Systematic Review and Meta-Analysis of 20 Double-Blind, Randomized, Placebo-Controlled Trials
Authors:
- 13 March 2023
- journal article
- research article
- Published by Elsevier in The American Journal of Medicine
- Vol. 136 (6) , 558-567.e20
Abstract
No abstract availableKeywords
Funding Information
- Eli Lilly and Company
- Roche
- National Health and Medical Research Council (APP1175744, APP1176494)
This publication has 42 references indexed in Scilit:
- A Phase 3 Study of Evolocumab (AMG 145) in Statin-Treated Japanese Patients at High Cardiovascular RiskThe American Journal of Cardiology, 2016
- Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I studyAmerican Heart Journal, 2015
- Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular EventsNew England Journal of Medicine, 2015
- PCSK9 is a critical regulator of the innate immune response and septic shock outcomeScience Translational Medicine, 2014
- Effect of Evolocumab or Ezetimibe Added to Moderate- or High-Intensity Statin Therapy on LDL-C Lowering in Patients With HypercholesterolemiaJAMA, 2014
- A 52-Week Placebo-Controlled Trial of Evolocumab in HyperlipidemiaNew England Journal of Medicine, 2014
- Preventing Cardiovascular Complications of Acute InfectionCirculation, 2014
- Acute pneumonia and the cardiovascular systemThe Lancet, 2013
- Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 studyThe Lancet, 2012
- The impact of diabetes on the pathogenesis of sepsisEuropean Journal of Clinical Microbiology & Infectious Diseases, 2011